Published in J Virol on October 25, 2006
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell (2013) 6.47
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol (2007) 4.64
Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol (2007) 3.93
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog (2007) 2.81
Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. PLoS Pathog (2008) 2.59
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol (2008) 2.56
Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. J Exp Med (2009) 2.39
HIV-1 group M conserved elements vaccine. PLoS Pathog (2007) 2.28
HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog (2009) 2.15
Viral sequence evolution in acute hepatitis C virus infection. J Virol (2007) 2.13
Rapid, complex adaptation of transmitted HIV-1 full-length genomes in subtype C-infected individuals with differing disease progression. AIDS (2013) 2.04
Dynamics of immune escape during HIV/SIV infection. PLoS Comput Biol (2008) 1.54
Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog (2012) 1.50
Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog (2009) 1.49
Frequent toggling between alternative amino acids is driven by selection in HIV-1. PLoS Pathog (2008) 1.49
Unequal evolutionary rates in the human immunodeficiency virus type 1 (HIV-1) pandemic: the evolutionary rate of HIV-1 slows down when the epidemic rate increases. J Virol (2007) 1.47
Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog (2011) 1.42
Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. J Virol (2011) 1.41
Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J Virol (2008) 1.38
An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). J Infect Dis (2011) 1.37
Patterns of antigenic diversity and the mechanisms that maintain them. J R Soc Interface (2007) 1.37
Vaccination and timing influence SIV immune escape viral dynamics in vivo. PLoS Pathog (2008) 1.34
HLA footprints on human immunodeficiency virus type 1 are associated with interclade polymorphisms and intraclade phylogenetic clustering. J Virol (2009) 1.30
Transmission and long-term stability of compensated CD8 escape mutations. J Virol (2008) 1.29
Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers. J Acquir Immune Defic Syndr (2011) 1.27
CD8 T cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense transcription. J Exp Med (2010) 1.27
Viral evolution and escape during acute HIV-1 infection. J Infect Dis (2010) 1.26
Frequent and variable cytotoxic-T-lymphocyte escape-associated fitness costs in the human immunodeficiency virus type 1 subtype B Gag proteins. J Virol (2013) 1.14
HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection. J Virol (2008) 1.13
In vivo fitness costs of different Gag CD8 T-cell escape mutant simian-human immunodeficiency viruses for macaques. J Virol (2007) 1.11
Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. Nat Rev Microbiol (2015) 1.08
Modelling the evolution and spread of HIV immune escape mutants. PLoS Pathog (2010) 1.06
Timing constraints of in vivo gag mutations during primary HIV-1 subtype C infection. PLoS One (2009) 1.06
Fluidity of HIV-1-specific T-cell responses during acute and early subtype C HIV-1 infection and associations with early disease progression. J Virol (2010) 1.04
Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study. Retrovirology (2009) 1.04
HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. PLoS One (2013) 1.03
Intra-host evolutionary rates in HIV-1C env and gag during primary infection. Infect Genet Evol (2013) 1.01
Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity. J Virol (2011) 0.99
Population genomics of intrapatient HIV-1 evolution. Elife (2015) 0.99
Molecular evolution of human immunodeficiency virus type 1 upon transmission between human leukocyte antigen disparate donor-recipient pairs. PLoS One (2008) 0.96
Primary isolates of human immunodeficiency virus type 1 are usually dominated by the major variants found in blood. J Virol (2007) 0.94
Adaptive changes in HIV-1 subtype C proteins during early infection are driven by changes in HLA-associated immune pressure. Virology (2009) 0.93
Inferring HIV Escape Rates from Multi-Locus Genotype Data. Front Immunol (2013) 0.91
Novel cytotoxic T-lymphocyte escape mutation by a three-amino-acid insertion in the human immunodeficiency virus type 1 p6Pol and p6Gag late domain associated with drug resistance. J Virol (2007) 0.90
Complexity of the inoculum determines the rate of reversion of SIV Gag CD8 T cell mutant virus and outcome of infection. PLoS Pathog (2009) 0.89
Rare HLA drive additional HIV evolution compared to more frequent alleles. AIDS Res Hum Retroviruses (2009) 0.88
When HIV spread afar. Proc Natl Acad Sci U S A (2007) 0.86
Tracking the culprit: HIV-1 evolution and immune selection revealed by single-genome amplification. J Exp Med (2009) 0.86
CD8+ T cell escape mutations in simian immunodeficiency virus SIVmac239 cause fitness defects in vivo, and many revert after transmission. J Virol (2011) 0.86
Cytotoxic T-lymphocyte escape mutations identified by HLA association favor those which escape and revert rapidly. J Virol (2012) 0.85
The specificity and polymorphism of the MHC class I prevents the global adaptation of HIV-1 to the monomorphic proteasome and TAP. PLoS One (2008) 0.85
Sequence evolution of HIV-1 following mother-to-child transmission. J Virol (2010) 0.84
Frequent associations between CTL and T-Helper epitopes in HIV-1 genomes and implications for multi-epitope vaccine designs. BMC Microbiol (2010) 0.84
Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development. Adv Virol (2012) 0.82
Relaxation of adaptive evolution during the HIV-1 infection owing to reduction of CD4+ T cell counts. PLoS One (2012) 0.81
The Effect of Interference on the CD8(+) T Cell Escape Rates in HIV. Front Immunol (2015) 0.79
Early immune adaptation in HIV-1 revealed by population-level approaches. Retrovirology (2014) 0.79
Modelling the spread of HIV immune escape mutants in a vaccinated population. PLoS Comput Biol (2011) 0.78
Evolutionary gamut of in vivo Gag substitutions during early HIV-1 subtype C infection. Virology (2011) 0.78
Reversion and T cell escape mutations compensate the fitness loss of a CD8+ T cell escape mutant in their cognate transmitted/founder virus. PLoS One (2014) 0.78
Low level of HIV-1 evolution after transmission from mother to child. Sci Rep (2014) 0.76
Investigating the Consequences of Interference between Multiple CD8+ T Cell Escape Mutations in Early HIV Infection. PLoS Comput Biol (2016) 0.76
Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection. J Virol (2015) 0.76
Newly Exerted T Cell Pressures on Mutated Epitopes following Transmission Help Maintain Consensus HIV-1 Sequences. PLoS One (2015) 0.75
In vivo mutation rates and the landscape of fitness costs of HIV-1. Virus Evol (2017) 0.75
Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic. J Virol (2015) 0.75
In vivo virulence of MHC-adapted AIDS virus serially-passaged through MHC-mismatched hosts. PLoS Pathog (2017) 0.75
Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells. J Clin Invest (2017) 0.75
The Alphabet Soup of HIV Reservoir Markers. Curr HIV/AIDS Rep (2017) 0.75
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55
Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med (1997) 12.26
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science (2002) 9.17
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science (1999) 8.11
Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A (1997) 8.05
Evolution and transmission of stable CTL escape mutations in HIV infection. Nature (2001) 6.57
Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med (2001) 6.51
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33
Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol (2006) 6.30
T cell dynamics in HIV-1 infection. Annu Rev Immunol (2001) 5.29
Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med (2002) 5.17
Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med (2004) 4.52
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42
Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med (2004) 4.37
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature (2002) 4.20
Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol (2004) 4.12
Advantage of rare HLA supertype in HIV disease progression. Nat Med (2003) 4.08
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med (2005) 3.68
Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med (2004) 3.48
Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol (2002) 3.38
Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol (2006) 3.20
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med (2004) 2.99
Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis (2003) 2.98
Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis (2003) 2.92
CD8 epitope escape and reversion in acute HCV infection. J Exp Med (2004) 2.77
Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol (2003) 2.64
Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol (2003) 2.53
Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol (2003) 2.40
Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. Virology (1995) 2.38
A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol (2004) 2.33
Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection. J Immunol (2003) 2.21
Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16
Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol (2002) 2.14
Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J Virol (2004) 2.12
Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J Virol (2004) 2.09
Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection. J Clin Invest (1999) 2.00
Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. J Virol Methods (2006) 1.99
Full-length sequence of an ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C. AIDS Res Hum Retroviruses (1996) 1.92
Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host. J Virol (2006) 1.82
Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol (2005) 1.77
Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods (2003) 1.73
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J Exp Med (2006) 1.72
Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies. J Infect Dis (2004) 1.64
Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J Virol (2003) 1.57
Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa. J Immunol (2004) 1.50
Gradual adaptation of HIV to human host populations: good or bad news? Nat Med (2003) 1.46
Screening for HIV-specific T-cell responses using overlapping 15-mer peptide pools or optimized epitopes. AIDS (2004) 1.38
Limited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection. J Virol (2005) 1.29
CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. J Immunol (2005) 1.21
Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes. J Virol (2005) 1.21
Inverse correlation between memory Gag-specific cytotoxic T lymphocytes and viral replication in human immunodeficiency virus-infected children. J Infect Dis (2002) 1.18
HIV-specific cellular immune response is inversely correlated with disease progression as defined by decline of CD4+ T cells in relation to HIV RNA load. J Infect Dis (2004) 0.98
CTL escape and increased viremia irrespective of HIV-specific CD4+ T-helper responses in two HIV-infected individuals. Virology (2005) 0.95
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature (2004) 9.53
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods (2004) 6.89
The case for boosting infant male circumcision in the face of rising heterosexual transmission of HIV. Med J Aust (2010) 5.94
Relation between HIV viral load and infectiousness: a model-based analysis. Lancet (2008) 5.74
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS (2003) 5.28
Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med (2002) 5.17
Cancer incidence before and after kidney transplantation. JAMA (2006) 4.77
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2006) 4.71
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol (2007) 4.64
Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55
Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med (2004) 4.52
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet (2006) 4.45
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol (2007) 4.41
Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med (2004) 4.37
Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med (2009) 4.22
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature (2002) 4.20
HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19
Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med (2007) 4.14
Mass Drug Administration for Scabies Control in a Population with Endemic Disease. N Engl J Med (2015) 4.06
Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol (2007) 3.93
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71
Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol (2003) 3.64
Unprotected anal intercourse, risk reduction behaviours, and subsequent HIV infection in a cohort of homosexual men. AIDS (2009) 3.61
Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature (2010) 3.57
Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med (2008) 3.48
Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol (2002) 3.38
Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog (2012) 3.35
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis (2009) 3.32
Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog (2011) 3.29
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 3.24
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol (2006) 3.20
The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr (2005) 3.18
Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest (2010) 3.15
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med (2012) 3.12
Characterization of CD4(+) CTLs ex vivo. J Immunol (2002) 3.10
AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med (2005) 2.97
Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial. AIDS (2005) 2.94
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 2.91
HIV prevention research in a resource-limited setting: the experience of planning a trial in Cambodia. Lancet (2005) 2.83
CD8 epitope escape and reversion in acute HCV infection. J Exp Med (2004) 2.77
MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol (2007) 2.77
Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (2003) 2.69
Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS (2010) 2.65
HIV-1 adaptation to NK-cell-mediated immune pressure. Nature (2011) 2.59
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology (2010) 2.56
Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol (2003) 2.53
Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol (2009) 2.51
Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis (2012) 2.51
Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood (2005) 2.50
Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J Virol (2002) 2.50
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet (2004) 2.43
Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis (2009) 2.43
Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis (2010) 2.41
Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. Proc Natl Acad Sci U S A (2011) 2.37
HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet (2004) 2.36
Immune-driven recombination and loss of control after HIV superinfection. J Exp Med (2008) 2.34
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS (2007) 2.27
"Serosorting" in casual anal sex of HIV-negative gay men is noteworthy and is increasing in Sydney, Australia. AIDS (2006) 2.26
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol (2005) 2.24